-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Insiders Probably Made the Right Decision Selling CN¥665m Worth of Shares Earlier This Year as CanSino Biologics Inc.'s (HKG:6185)) Stock Dips by 11%.
Insiders Probably Made the Right Decision Selling CN¥665m Worth of Shares Earlier This Year as CanSino Biologics Inc.'s (HKG:6185)) Stock Dips by 11%.
By selling CN¥665m worth of CanSino Biologics Inc. (HKG:6185) stock at an average sell price of CN¥70.50 over the last year, insiders seemed to have made the most of their holdings. The company's market cap plunged by HK$1.6b after price dropped by 11% last week but insiders were able to limit their loss to an extent.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
See our latest analysis for CanSino Biologics
CanSino Biologics Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider sale was by the insider, Shi Yi, for HK$665m worth of shares, at about HK$70.50 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (HK$53.20). So it is hard to draw any strong conclusion from it. Shi Yi was the only individual insider to sell over the last year.
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
SEHK:6185 Insider Trading Volume August 30th 2022If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).
Does CanSino Biologics Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. CanSino Biologics insiders own about HK$10b worth of shares (which is 42% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
What Might The Insider Transactions At CanSino Biologics Tell Us?
It doesn't really mean much that no insider has traded CanSino Biologics shares in the last quarter. While we feel good about high insider ownership of CanSino Biologics, we can't say the same about the selling of shares. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example - CanSino Biologics has 1 warning sign we think you should be aware of.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
通过出售价值6.65亿元的CN坎西诺生物公司。(HKG:6185)股票过去一年的平均售价为70.50元,内部人士似乎充分利用了他们所持的股份。在上周股价下跌11%后,该公司市值暴跌16亿港元,但内部人士能够在一定程度上限制他们的损失。
虽然我们永远不会建议投资者应该完全根据公司董事的所作所为做出决定,但我们认为完全忽视内幕交易是愚蠢的。
查看我们对佳华生物的最新分析
Cansino Biologics去年的内幕交易
过去一年,我们可以看到,最大的内幕交易是内部人士施义以每股约70.5港元的价格,购买了价值6.65亿港元的股票。虽然我们通常不喜欢看到内幕出售,但如果以更低的价格出售,人们更担心的是。一线希望是,此次抛售发生在最新股价(53.20港元)之上。因此,很难从中得出任何强有力的结论。施义是过去一年中唯一抛售的个人内部人士。
你可以在下面看到过去12个月(由公司和个人)进行的内幕交易的直观描述。通过点击下面的图表,你可以看到每一笔内幕交易的准确细节!
联交所:2022年8月30日内幕交易量6185如果你喜欢购买内部人士正在买入的股票,而不是抛售,那么你可能会喜欢这一点免费公司名单。(提示:内部人士一直在买入这些股票)。
中信生物拥有高度的内部人持股吗?
对于一个普通股股东来说,公司内部人士持有多少股份值得一查。通常,内部人持股越高,内部人就越有可能受到激励,建立长期的公司。Cansino Biologics内部人士持有价值约100亿港元的股份(占公司股份的42%)。这种由内部人士持有的重大所有权通常确实增加了公司以所有股东的利益运营的机会。
佳信生物的内幕交易可能告诉我们什么?
上个季度没有内部人士交易佳华生物的股票,这并不意味着什么。虽然我们对嘉信生物的高内部人持股感到满意,但我们不能对出售股份的行为说同样的话。虽然我们喜欢知道内部人士的所有权和交易情况,但在做出任何投资决定之前,我们也要确保考虑到一只股票面临的风险。例如-佳华生物有1个警告标志我们认为你应该意识到。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费列出了一些有趣的公司,这些公司拥有高股本回报率和低债务。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧